Tailoring the Cell Line Development Process to the Specific Molecule and the Program Goals

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Speed and efficiency remain major drivers for developers bringing their protein-based biologics to first in human studies. The right cell line development approach can help streamline the path to clinic for both standard monoclonal antibodies and more complex modalities such as bispecifics. During this presentation, we share the latest data on how the GPEx® suite of technologies enables high titers, short timelines and flexibility in cell line development for mammalian-expressed proteins.
Speaker
photo
Vice President of Research and Development
Catalent Biologics